Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Pharmaceutical Services Selected by Lundbeck To Provide VYEPTI\u2122 (eptinezumab-jjmr) ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Pharmaceutical Services Expands Partnership With Ultragenyx To Provide Dojolvi\u2122 (triheptanoin)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Expands Partnership With Alnylam\u00ae Pharmaceuticals as a Limited Distribution Partner For OXLUMO\u2122 (lumasiran)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Selected as Limited Distribution Partner for Amvuttra\u2122 (vutrisiran)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution Partner for HEMGENIX\u00ae, the First and Only Gene Therapy for Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Krystal Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orsini Specialty Pharmacy Selected as part of the Limited Specialty Pharmacy Network For VYJUVEK\u2122, the First Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orsini Specialty Pharmacy Now Dispensing VOWST (fecal microbiota spores, live - brpk) Capsules for Oral Administration for the Prevention of Recurrence of C. Difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orsini Selected by BioMarin to Dispense ROCTAVIAN, the First Gene Therapy for the Treatment of Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ\u2122 (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Orsini Pharmaceutical

    Menu

    Orsini Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Orsini Specialty Pharmacy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease

              Details:

              Under the agreement, Orsini will dispense Pombiliti™ (cipaglucosidase alfa-atga), a hydrolytic lysosomal glycogen-specific enzyme, and Opfolda™ (miglustat), a two-component treatment approved for certain patients with late-onset Pompe disease.

              Lead Product(s): Cipaglucosidase Alfa,Miglustat

              Therapeutic Area: Genetic Disease Product Name: Pombiliti

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Amicus Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease

              Details:

              Under the agreement, Orsini will be the exclusive specialty pharmacy partner for Veopoz (pozelimab-bbfg), a monoclonal antibody and the first and only treatment for those living with CHAPLE disease.

              Lead Product(s): Pozelimab-bbfg

              Therapeutic Area: Rare Diseases and Disorders Product Name: Veopoz

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Selected by BioMarin to Dispense ROCTAVIAN, the First Gene Therapy for the Treatment of Severe Hemophilia A

              Details:

              Roctavian (valoctocogene roxaparvovec) is a gene therapy that uses an adeno-associated virus 5, codes for human Factor VIII, together with a human liver-specific promoter. It is currently being investigated for adults with severe hemophilia A.

              Lead Product(s): Valoctocogene Roxaparvovec-rvox

              Therapeutic Area: Genetic Disease Product Name: Roctavian

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: BioMarin Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Specialty Pharmacy Now Dispensing VOWST (fecal microbiota spores, live - brpk) Capsules for Oral Administration for the Prevention of Recurrence of C. Difficile Infe...

              Details:

              Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).

              Lead Product(s): Fecal Microbiota Spores Live-brpk

              Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Specialty Pharmacy Selected as part of the Limited Specialty Pharmacy Network For VYJUVEK™, the First Gene Therapy for the Treatment of Dystrophic Epidermolysis Bu...

              Details:

              Vyjuvek (beremagene geperpavec-svdt) is a non-invasive, topical, redosable gene therapy designed to deliver two copies of the COL7A1 gene when applied directly to DEB wounds. Vyjuvek received FDA Approval for the First-Ever Redosable Gene Therapy for DEB treatment.

              Lead Product(s): Beremagene Geperpavec-svdt

              Therapeutic Area: Genetic Disease Product Name: Vyjuvek

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Recipient: Krystal Biotech

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution Partner for HEMGENIX®, the First and Only Gene Therapy for Hemophilia B

              Details:

              Hemgenix (etranacogene dezaparvovec-drlb) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B who Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemorrhage.

              Lead Product(s): Etranacogene Dezaparvovec-drlb

              Therapeutic Area: Genetic Disease Product Name: Hemgenix

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Recipient: CSL Behring

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Specialty Pharmacy Selected as Limited Distribution Partner for Amvuttra™ (vutrisiran)

              Details:

              AMVUTTRA (vutrisiran), is indicated to treat the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The drug works to reduce the production of the transthyretin (TTR) protein in the liver, thereby reducing the levels of TTR in the body.

              Lead Product(s): Vutrisiran

              Therapeutic Area: Genetic Disease Product Name: Amvuttra

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership July 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals as a Limited Distribution Partner For OXLUMO™ (lumasiran)

              Details:

              Orsini Specialty Pharmacy been selected by Alnylam® Pharmaceuticals as a limited distribution partner for OXLUMO™. OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

              Lead Product(s): Lumasiran

              Therapeutic Area: Genetic Disease Product Name: Oxlumo

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Pharmaceutical Services Expands Partnership With Ultragenyx To Provide Dojolvi™ (triheptanoin)

              Details:

              Orsini Pharmaceutical Services has been selected by Ultragenyx Pharmaceutical as a limited distribution specialty pharmacy partner for Dojolvi (triheptanoin). Dojolvi™ is indicated as a source of calories and fatty acids for the treatment of molecularly confirmed LC-FAOD.

              Lead Product(s): Triheptanoin

              Therapeutic Area: Genetic Disease Product Name: Dojolvi

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ultragenyx Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership July 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orsini Specialty Pharmacy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orsini Pharmaceutical Services Selected by Lundbeck To Provide VYEPTI™ (eptinezumab-jjmr)

              Details:

              Orsini Pharmaceutical has been selected as one of a very limited number of distribution partners for VYEPTI™ (eptinezumab-jjmr).

              Lead Product(s): Eptinezumab

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: H. Lundbeck AS

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY